Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Volpara Health Technologies Limited

ARN

NZCN: 2206998 ARBN: 609 946 867

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

+Class of +securities issued or to be issued Options over ordinary shares (**Options**)

Number of *securities issued or to be issued (if known) or maximum number which may be issued

900,000 Options (two separate issuances of 450,000 Options)

Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)

Exercise price: A\$0.60

Expiry dates: 22 March 2025 and 23 August 2025, respectively

Vesting dates: 40% two years from grant date; 20% 3 years from grant date; 20% 4 years from grant date and 20% 5 years from grant date

⁺ See chapter 19 for defined terms.

Shares issued on exercise of the Options will Do the *securities rank equally in 4 rank equally in all respects with existing all respects from the +issue date with an existing +class of quoted ordinary shares on issue. +securities? If the additional *securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment Nil Issue price or consideration 5 6 Purpose of the issue Options issued to new directors to encourage (If issued as consideration for the long-term alignment of new directors and acquisition of assets, clearly shareholders. identify those assets) 6a Is the entity an +eligible entity Yes that has obtained security holder approval under rule 7.1A?

comply with section 6i

6b

If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and

The date the security holder

resolution under rule 7.1A was

23 August 2018

passed

⁺ See chapter 19 for defined terms.

6c	Number of *securities issued without security holder approval under rule 7.1	Nil
6d	Number of *securities issued with security holder approval under rule 7.1A	Nil
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil
6f	Number of *securities issued under an exception in rule 7.2	900,000 Options (two separate issuances of 450,000 Options) Exception 14: Approved by holders of ordinary securities under Listing Rule 10.11.
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Rule 7.1: 26,873,423 Rule 7.1A: 17,915,615

⁺ See chapter 19 for defined terms.

7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

Granted unconditionally on 23 August 2018 following receipt of shareholder approval

8 Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)

Number	+Class
179,156,158	Ordinary Shares
	(includes 51,482,213
	shares under
	voluntary escrow, i.e.
	until 30 April 2019).

9 Number and *class of all *securities not quoted on ASX (*including* the *securities in section 2 if applicable)

Number	+Class
12,434,162	Options over fully
	paid ordinary shares,
	exercisable at
	various prices by
	various dates (noting
	31,200 options have
	been forfeited since
	last Appendix 3B
	lodged on 7 August
	2018 and 450,000 of
	Options the subject
	of this 3B were
	inadvertently
	included in the total
	for item 9 of the 3B
	lodged with ASX on
	13 April 2018
	although the issue of
	those Options was
	not approved by
	shareholders until 23
	August 2018.

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A

Part 2 - Pro rata issue

⁺ See chapter 19 for defined terms.

11	Is security holder approval N/A required?	
	7 .1 · 11	
12	Is the issue renounceable or non-renounceable?	
	D 1 . 1 . 1 +	
13	Ratio in which the *securities will N/A be offered	
1.4	*Class of *securities to which the N/A	
14	offer relates	
15	⁺ Record date to determine N/A	
15	entitlements	
16	Will holdings on different N/A	
10	registers (or subregisters) be	
	aggregated for calculating	
	entitlements?	
	D. 1. (1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1	
17	Policy for deciding entitlements N/A in relation to fractions	
	in relation to fractions	
18	Names of countries in which the N/A	
	entity has security holders who	
	will not be sent new offer documents	
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
	Clasina data Camanasint of NI/A	
19	Closing date for receipt of N/A acceptances or renunciations	
20	Names of any underwriters N/A	
20	Traines of any anaerwiters	
21	Amount of any underwriting fee N/A or commission	
	OI COMMISSION	
22	Names of any brokers to the issue N/A	
	, 11,11	
	p	
23	Fee or commission payable to the N/A	

⁺ See chapter 19 for defined terms.

24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	⁺ Issue date	N/A

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

Type of *securities (tick one)

⁺ See chapter 19 for defined terms.

(a)	χ	+Securities described in Part 1		
(b)		All other ⁺ securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities		
Entities	s that	have ticked box 34(a)		
Additio	onal s	ecurities forming a new class of securities		
Tick to docume		e you are providing the information or		
35		If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders		
36		If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over		
37		A copy of any trust deed for the additional *securities		
Entities	s that	have ticked box 34(b)		
38		per of *securities for which ation is sought		
39		s of *securities for which tion is sought		

⁺ See chapter 19 for defined terms.

40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now		
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Ni-mah on	+Class
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)	Number	+Class
Quota	tion agreement		

Ç

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX 1 may quote the +securities on any conditions it decides.
- We warrant the following to ASX. 2
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those +securities should not be granted +quotation.

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

• An offer of the †securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 12 September 20	Sign here:	CY/IM II /	Date: 12 September 20
----------------------------------	------------	------------	-----------------------

(Company secretary)

Print name: Craig Hadfield

== == == ==

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	145,193,121	
 Add the following: Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2 Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval Number of partly paid +ordinary securities that became fully paid in that 12 month period Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of 	300,000 (20/11/17) 25,000,000 (07/05/18) (ratified by shareholders on 23/08/18) 20,000 (16/05/18) 8,333,037 (31/05/18) 168,000 (15/06/18) 142,000 (6/08/18)	
securities on different dates as separate line items Subtract the number of fully paid +ordinary securities cancelled during that 12 month period	Nil	
"A"	179,156,158	

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
Multiply "A" by 0.15	26,873,423	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
Insert number of *equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	Nil	
• Under an exception in rule 7.2		
Under rule 7.1A		
 With security holder approval under rule 7.1 or rule 7.4 		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"	Nil	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15	26,873,423	
Note: number must be same as shown in Step 2		
Subtract "C"	Nil	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	26,873,423[Note: this is the remaining placement capacity under rule 7.1]	

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A" 179,156,158		
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	17,915,615	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	Nil	
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 		
"E"	Nil	

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10 17,915,615		
Note: number must be same as shown in Step 2		
Subtract "E"	Nil	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.10] – "E"	17,915,615Note: this is the remaining placement capacity under rule 7.1A	

⁺ See chapter 19 for defined terms.